Plasma insulin is required for the increase in plasma angiopoietin‐like protein 8 in response to nutrient ingestion

Plasma levels of angiopoietin‐like protein 8 (ANGPTL8) are regulated by feeding and they increase following glucose ingestion. Because both plasma glucose and insulin increase following food ingestion, we aimed to determine whether the increase in plasma insulin and glucose or both are responsible for the increase in ANGPTL8 levels.

[1]  R. Siegel,et al.  An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif , 2022, Journal of lipid research.

[2]  Ren Zhang,et al.  An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues. , 2021, Progress in lipid research.

[3]  B. Rodrigues,et al.  Lipoprotein Lipase and Its Delivery of Fatty Acids to the Heart , 2021, Biomolecules.

[4]  M. Rizzo,et al.  Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease , 2021, Metabolites.

[5]  K. Alzoubi,et al.  Exploring perception and hesitancy toward COVID-19 vaccine: A study from Jordan , 2021, Human vaccines & immunotherapeutics.

[6]  Y. Qian,et al.  ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition , 2021, Journal of lipid research.

[7]  M. Prentki,et al.  The multi-faces of Angptl8 in health and disease: Novel functions beyond lipoprotein lipase modulation. , 2020, Progress in lipid research.

[8]  P. Cluzel,et al.  High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects , 2020, Diabetes/metabolism research and reviews.

[9]  F. V. van’t Hooft,et al.  Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids[S] , 2020, Journal of Lipid Research.

[10]  M. Abdul-Ghani,et al.  Regulation of ANGPTL8 in Liver and Adipose Tissue by Nutritional and Hormonal Signals and its Effect on Glucose Homeostasis in Mice. , 2020, American journal of physiology. Endocrinology and metabolism.

[11]  M. Ploug,et al.  On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity , 2019, Journal of Lipid Research.

[12]  S. Kalyon,et al.  Serum Angiopoietin‐like peptide 4 levels in patients with hepatic steatosis , 2018, Cytokine.

[13]  J. Tuomilehto,et al.  ANGPTL8 (betatrophin) role in diabetes and metabolic diseases , 2017, Diabetes/metabolism research and reviews.

[14]  S. Kersten.  Angiopoietin-like 3 in lipoprotein metabolism , 2017, Nature Reviews Endocrinology.

[15]  S. Shetty,et al.  ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase , 2017, Molecular metabolism.

[16]  Jonathan C. Cohen,et al.  ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[S] , 2017, Journal of Lipid Research.

[17]  Mingfeng Xia,et al.  Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population , 2017, PloS one.

[18]  Ren Zhang.  The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking , 2016, Open Biology.

[19]  M. Abu-Farha,et al.  Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome , 2016, Cardiovascular Diabetology.

[20]  P. Fischer-Posovszky,et al.  Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin. , 2015, The Journal of clinical endocrinology and metabolism.

[21]  F. Hu,et al.  Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance , 2015, Scientific Reports.

[22]  Indra Ramasamy,et al.  Recent advances in physiological lipoprotein metabolism , 2014, Clinical chemistry and laboratory medicine.

[23]  Libin Zhou,et al.  Increased Circulating Levels of Betatrophin in Newly Diagnosed Type 2 Diabetic Patients , 2014, Diabetes Care.

[24]  F. Sacks,et al.  Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case–Control Study in 13 Countries , 2013, Circulation.

[25]  Jonathan C. Cohen,et al.  Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis , 2013, Proceedings of the National Academy of Sciences.

[26]  Y. Li,et al.  Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study , 2013, Cardiovascular Diabetology.

[27]  Jonathan C. Cohen,et al.  Atypical angiopoietin-like protein that regulates ANGPTL3 , 2012, Proceedings of the National Academy of Sciences.

[28]  Ji Young Kim,et al.  Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. , 2012, American journal of physiology. Endocrinology and metabolism.

[29]  P. Tso,et al.  The mechanism of the formation and secretion of chylomicrons. , 2010, Atherosclerosis. Supplements.

[30]  A. Mooradian.  Dyslipidemia in type 2 diabetes mellitus , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[31]  Robert A. Hegele,et al.  Plasma lipoproteins: genetic influences and clinical implications , 2009, Nature Reviews Genetics.

[32]  C. Fraser,et al.  Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. , 2005, Endocrinology.

[33]  Sanjoy Ghosh,et al.  Evidence for rapid "metabolic switching" through lipoprotein lipase occupation of endothelial-binding sites. , 2003, Journal of molecular and cellular cardiology.

[34]  P. Sluijs,et al.  How proteins move lipids and lipids move proteins , 2001, Nature Reviews Molecular Cell Biology.

[35]  R. DeFronzo,et al.  Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance Results From the Veterans Administration Genetic Epidemiology Study , 2006 .

[36]  R. DeFronzo,et al.  Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. , 2006, Diabetes care.